BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 30978322)

  • 1. Structure-based design and in vivo anti-arthritic activity evaluation of a potent dipeptidyl cyclopropyl nitrile inhibitor of cathepsin C.
    Korkmaz B; Lesner A; Wysocka M; Gieldon A; Håkansson M; Gauthier F; Logan DT; Jenne DE; Lauritzen C; Pedersen J
    Biochem Pharmacol; 2019 Jun; 164():349-367. PubMed ID: 30978322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged pharmacological inhibition of cathepsin C results in elimination of neutrophil serine proteases.
    Guarino C; Hamon Y; Croix C; Lamort AS; Dallet-Choisy S; Marchand-Adam S; Lesner A; Baranek T; Viaud-Massuard MC; Lauritzen C; Pedersen J; Heuzé-Vourc'h N; Si-Tahar M; Fıratlı E; Jenne DE; Gauthier F; Horwitz MS; Borregaard N; Korkmaz B
    Biochem Pharmacol; 2017 May; 131():52-67. PubMed ID: 28193451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cathepsin C inhibition as a potential treatment strategy in cancer.
    Korkmaz B; Lamort AS; Domain R; Beauvillain C; Gieldon A; Yildirim AÖ; Stathopoulos GT; Rhimi M; Jenne DE; Kettritz R
    Biochem Pharmacol; 2021 Dec; 194():114803. PubMed ID: 34678221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo inhibition of serine protease processing requires a high fractional inhibition of cathepsin C.
    Méthot N; Guay D; Rubin J; Ethier D; Ortega K; Wong S; Normandin D; Beaulieu C; Reddy TJ; Riendeau D; Percival MD
    Mol Pharmacol; 2008 Jun; 73(6):1857-65. PubMed ID: 18326050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic targeting of cathepsin C: from pathophysiology to treatment.
    Korkmaz B; Caughey GH; Chapple I; Gauthier F; Hirschfeld J; Jenne DE; Kettritz R; Lalmanach G; Lamort AS; Lauritzen C; Łȩgowska M; Lesner A; Marchand-Adam S; McKaig SJ; Moss C; Pedersen J; Roberts H; Schreiber A; Seren S; Thakker NS
    Pharmacol Ther; 2018 Oct; 190():202-236. PubMed ID: 29842917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BI 1291583: a novel selective inhibitor of cathepsin C with superior in vivo profile for the treatment of bronchiectasis.
    Kreideweiss S; Schänzle G; Schnapp G; Vintonyak V; Grundl MA
    Inflamm Res; 2023 Aug; 72(8):1709-1717. PubMed ID: 37542002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophilic Cathepsin C Is Maturated by a Multistep Proteolytic Process and Secreted by Activated Cells during Inflammatory Lung Diseases.
    Hamon Y; Legowska M; Hervé V; Dallet-Choisy S; Marchand-Adam S; Vanderlynden L; Demonte M; Williams R; Scott CJ; Si-Tahar M; Heuzé-Vourc'h N; Lalmanach G; Jenne DE; Lesner A; Gauthier F; Korkmaz B
    J Biol Chem; 2016 Apr; 291(16):8486-99. PubMed ID: 26884336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic utility and medicinal chemistry of cathepsin C inhibitors.
    Guay D; Beaulieu C; Percival MD
    Curr Top Med Chem; 2010; 10(7):708-16. PubMed ID: 20337582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung Protection by Cathepsin C Inhibition: A New Hope for COVID-19 and ARDS?
    Korkmaz B; Lesner A; Marchand-Adam S; Moss C; Jenne DE
    J Med Chem; 2020 Nov; 63(22):13258-13265. PubMed ID: 32692176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and Optimization of Novel Cathepsin C Inhibitors Derived from EGFR Inhibitors.
    Hou W; Sun H; Ma Y; Liu C; Zhang Z
    J Med Chem; 2019 Jun; 62(12):5901-5919. PubMed ID: 31145622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing.
    Méthot N; Rubin J; Guay D; Beaulieu C; Ethier D; Reddy TJ; Riendeau D; Percival MD
    J Biol Chem; 2007 Jul; 282(29):20836-46. PubMed ID: 17535802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis.
    Adkison AM; Raptis SZ; Kelley DG; Pham CT
    J Clin Invest; 2002 Feb; 109(3):363-71. PubMed ID: 11827996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Premedication with a cathepsin C inhibitor alleviates early primary graft dysfunction in mouse recipients after lung transplantation.
    Rehm SRT; Smirnova NF; Morrone C; Götzfried J; Feuchtinger A; Pedersen J; Korkmaz B; Yildirim AÖ; Jenne DE
    Sci Rep; 2019 Jul; 9(1):9925. PubMed ID: 31289357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. E-64c-hydrazide: a lead structure for the development of irreversible cathepsin C inhibitors.
    Radzey H; Rethmeier M; Klimpel D; Grundhuber M; Sommerhoff CP; Schaschke N
    ChemMedChem; 2013 Aug; 8(8):1314-21. PubMed ID: 23780739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cathepsin C role in inflammatory gastroenterological, renal, rheumatic, and pulmonary disorders.
    Aghdassi AA; Pham C; Zierke L; Mariaule V; Korkmaz B; Rhimi M
    Biochimie; 2024 Jan; 216():175-180. PubMed ID: 37758158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and
    Chen X; Yan Y; Zhang Z; Zhang F; Liu M; Du L; Zhang H; Shen X; Zhao D; Shi JB; Liu X
    J Med Chem; 2021 Aug; 64(16):11857-11885. PubMed ID: 34374541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of dipeptidyl nitriles as potent, selective, and reversible inhibitors of cathepsin C.
    Guay D; Beaulieu C; Truchon JF; Jagadeeswar Reddy T; Zamboni R; Bayly CI; Methot N; Rubin J; Ethier D; David Percival M
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5392-6. PubMed ID: 19665376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cathepsin C modulates myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis.
    Durose WW; Shimizu T; Li J; Abe M; Sakimura K; Chetsawang B; Tanaka KF; Suzumura A; Tohyama K; Ikenaka K
    J Neurochem; 2019 Feb; 148(3):413-425. PubMed ID: 30152001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological inhibition of the cysteine protease cathepsin C improves graft function after heart transplantation in rats.
    Liu B; Korkmaz B; Kraft P; Mayer T; Sayour AA; Grundl MA; Domain R; Karck M; Szabó G; Korkmaz-Icöz S
    J Transl Med; 2023 Nov; 21(1):799. PubMed ID: 37946197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukocyte cathepsin C deficiency attenuates atherosclerotic lesion progression by selective tuning of innate and adaptive immune responses.
    Herías V; Biessen EA; Beckers C; Delsing D; Liao M; Daemen MJ; Pham CC; Heeneman S
    Arterioscler Thromb Vasc Biol; 2015 Jan; 35(1):79-86. PubMed ID: 25395616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.